INTRODUCTION: This study aims to review the magnetic resonance imaging (MRI) aspects of a large series of patients with focal cortical dysplasia type II (FCD II) and attempt to identify distinctive features in the two histopathological subtypes IIa and IIb. METHODS: We retrospectively reviewed the MRI scans of 118 patients with histological proven FCD IIa (n = 37) or IIb (n = 81) who were surgically treated for intractable epilepsy. RESULTS: MRI was abnormal in 93 patients (79 %) and unremarkable in 25 (21 %). A dysplastic lesion was identified in 90 cases (97 %) and classified as FCD II in 83 and FCD non-II in seven cases. In three cases, the MRI diagnosis was other than FCD. There was a significant association between the presence of cortical thickening (p = 0.002) and the "transmantle sign" (p < 0.001) and a correct MRI diagnosis of FCD II. MRI positivity was more frequent in the patients with FCD IIb than in those with FCD IIa (91 % vs. 51 %), and the detection rate of FCD II was also better in the patients with type IIb (88 % vs. 32 %). The transmantle sign was significantly more frequent in the IIb subgroup (p = 0.003). CONCLUSIONS: The rates of abnormal MRI results and correct MRI diagnoses of FCD II were significantly higher in the IIb subgroup. Although other MRI stigmata may contribute to the diagnosis, the only significant correlation was between the transmantle sign and FCD IIb.
INTRODUCTION: This study aims to review the magnetic resonance imaging (MRI) aspects of a large series of patients with focal cortical dysplasia type II (FCD II) and attempt to identify distinctive features in the two histopathological subtypes IIa and IIb. METHODS: We retrospectively reviewed the MRI scans of 118 patients with histological proven FCD IIa (n = 37) or IIb (n = 81) who were surgically treated for intractable epilepsy. RESULTS: MRI was abnormal in 93 patients (79 %) and unremarkable in 25 (21 %). A dysplastic lesion was identified in 90 cases (97 %) and classified as FCD II in 83 and FCD non-II in seven cases. In three cases, the MRI diagnosis was other than FCD. There was a significant association between the presence of cortical thickening (p = 0.002) and the "transmantle sign" (p < 0.001) and a correct MRI diagnosis of FCD II. MRI positivity was more frequent in the patients with FCD IIb than in those with FCD IIa (91 % vs. 51 %), and the detection rate of FCD II was also better in the patients with type IIb (88 % vs. 32 %). The transmantle sign was significantly more frequent in the IIb subgroup (p = 0.003). CONCLUSIONS: The rates of abnormal MRI results and correct MRI diagnoses of FCD II were significantly higher in the IIb subgroup. Although other MRI stigmata may contribute to the diagnosis, the only significant correlation was between the transmantle sign and FCD IIb.
Authors: S K Kim; D G Na; H S Byun; S E Kim; Y L Suh; J Y Choi; H K Yoon; B K Han Journal: J Comput Assist Tomogr Date: 2000 Mar-Apr Impact factor: 1.826
Authors: Anne T Berg; Barbara G Vickrey; John T Langfitt; Michael R Sperling; Thaddeus S Walczak; Shlomo Shinnar; Carl W Bazil; Steven V Pacia; Susan S Spencer Journal: Epilepsia Date: 2003-11 Impact factor: 5.864
Authors: Nadia Colombo; Laura Tassi; Carlo Galli; Alberto Citterio; Giorgio Lo Russo; Giuseppe Scialfa; Roberto Spreafico Journal: AJNR Am J Neuroradiol Date: 2003-04 Impact factor: 3.825
Authors: R A Bronen; K P Vives; J H Kim; R K Fulbright; S S Spencer; D D Spencer Journal: AJNR Am J Neuroradiol Date: 1997 Jun-Jul Impact factor: 3.825
Authors: Angelika Mühlebner; Roland Coras; Katja Kobow; Martha Feucht; Thomas Czech; Hermann Stefan; Daniel Weigel; Michael Buchfelder; Hans Holthausen; Tom Pieper; Manfred Kudernatsch; Ingmar Blümcke Journal: Acta Neuropathol Date: 2011-11-27 Impact factor: 17.088
Authors: A C Bastos; R M Comeau; F Andermann; D Melanson; F Cendes; F Dubeau; S Fontaine; D Tampieri; A Olivier Journal: Ann Neurol Date: 1999-07 Impact factor: 10.422
Authors: Ingmar Blümcke; Maria Thom; Eleonora Aronica; Dawna D Armstrong; Harry V Vinters; Andre Palmini; Thomas S Jacques; Giuliano Avanzini; A James Barkovich; Giorgio Battaglia; Albert Becker; Carlos Cepeda; Fernando Cendes; Nadia Colombo; Peter Crino; J Helen Cross; Olivier Delalande; François Dubeau; John Duncan; Renzo Guerrini; Philippe Kahane; Gary Mathern; Imad Najm; Ciğdem Ozkara; Charles Raybaud; Alfonso Represa; Steven N Roper; Noriko Salamon; Andreas Schulze-Bonhage; Laura Tassi; Annamaria Vezzani; Roberto Spreafico Journal: Epilepsia Date: 2010-11-10 Impact factor: 5.864
Authors: N Salamon; J Kung; S J Shaw; J Koo; S Koh; J Y Wu; J T Lerner; R Sankar; W D Shields; J Engel; I Fried; H Miyata; W H Yong; H V Vinters; G W Mathern Journal: Neurology Date: 2008-11-11 Impact factor: 9.910
Authors: Laura A Jansen; Ghayda M Mirzaa; Gisele E Ishak; Brian J O'Roak; Joseph B Hiatt; William H Roden; Sonya A Gunter; Susan L Christian; Sarah Collins; Carissa Adams; Jean-Baptiste Rivière; Judith St-Onge; Jeffrey G Ojemann; Jay Shendure; Robert F Hevner; William B Dobyns Journal: Brain Date: 2015-02-25 Impact factor: 13.501
Authors: Hans Holthausen; Tom Pieper; Peter Winkler; Ingmar Bluemcke; Manfred Kudernatsch Journal: Childs Nerv Syst Date: 2014-09-27 Impact factor: 1.475
Authors: Shai Shrot; Misun Hwang; Carl E Stafstrom; Thierry A G M Huisman; Bruno P Soares Journal: Neuroradiology Date: 2017-12-26 Impact factor: 2.804
Authors: Seok-Jun Hong; Boris C Bernhardt; Benoit Caldairou; Jeffery A Hall; Marie C Guiot; Dewi Schrader; Neda Bernasconi; Andrea Bernasconi Journal: Neurology Date: 2017-01-27 Impact factor: 9.910
Authors: Francesco Cardinale; Giuseppa Chinnici; Manuela Bramerio; Roberto Mai; Ivana Sartori; Massimo Cossu; Giorgio Lo Russo; Laura Castana; Nadia Colombo; Chiara Caborni; Elena De Momi; Giancarlo Ferrigno Journal: Neuroinformatics Date: 2014-10